• 我要登录|
  • 免费注册
    |
  • 我的丁香通
    • 企业机构:
    • 成为企业机构
    • 个人用户:
    • 个人中心
  • 移动端
    移动端
丁香通 logo丁香实验_LOGO
搜实验

    大家都在搜

      大家都在搜

        0 人通过求购买到了急需的产品
        免费发布求购
        发布求购
        点赞
        收藏
        wx-share
        分享

        Protamine Titration

        互联网

        489
        Protamine titration is the gold standard method for the measurement of unfractionated heparin (UFH) concentration in plasma. Protamine titration produces reliable and reproducible results; however it is �generally not considered a convenient assay for current clinical management of UFH as it is not readily automated (Olson et al. Arch Pathol Lab Med 122(9):782–798, 1998). Early clinical trials of UFH therapy determined that a heparin concentration of 0.2–0.4 U/ml by protamine titration correlated to an APTT of 1.5–2.5 times higher compared to baseline values produced desirable UFH safety and efficacy outcomes (Hull et al. N Engl J Med 315(18):1109–1114, 1986; Hull et al. N Engl J Med 322:1260–1264, 1990; Turpie et al. N Engl J Med 320:352–357, 1989; Brill-Edwards et al. Ann Intern Med 119(2):104–109, 1993; Hull Int Angiol 14(1):32–34, 1995). Such studies paved the way to the current view that it is no longer ideal to manage UFH based solely upon a 1.5–2.5 times prolongation of the “normal” APTT. Most advisory bodies recommend therapeutic APTTs be determined by correlating APTT results with therapeutic UFH levels as measured by anti-Xa assay (0.35–0.7 U/ml) or protamine titration (0.2–0.4 U/ml) (Hirsh and Raschke. Chest 126(3):188S-203S, 2004) (see Note 1 ).
        The concentration of UFH in a sample is measured by determining the amount of protamine required to return the thrombin clotting time (TCT) test (prolonged by UFH) to a pre-UFH level (Laffan and Manning. Dacie and Lewis: practical haematology. Churchill Livingstone: London, 2001).
        ad image
        提问
        扫一扫
        丁香实验小程序二维码
        实验小助手
        丁香实验公众号二维码
        扫码领资料
        反馈
        TOP
        打开小程序